

17. (Twice Amended) A composition, comprising a physiologically acceptable carrier and the polypeptide according to claim 63.

B2  
18. (Twice Amended) An immunogenic composition, comprising an immunostimulant and the polypeptide according to claim 63.

{ Please add new claim 63 to read as follows: }

B3  
63. (New) An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:308, or a portion thereof comprising at least 10 contiguous amino acids, wherein the polynucleotide encoding said polypeptide is over-expressed in breast tumor tissue as compared to normal breast tissue.

#### REMARKS

Claims 2-3, 17-20, and 62-63 are pending in this case. Claim 1 has been cancelled. Claim 63 has been added. Claims 4-17, 21-60 have been withdrawn from further consideration as being drawn to a non-elected invention.

Certain pending claims have been amended to expedite prosecution on certain preferred embodiments of the invention. It is urged that support for all the above amendments may be found throughout the specification as originally filed (see for example pages 9, 58-59, and 103) and that none of the amendments constitutes new matter. It should also be noted that the above amendments are not to be construed as acquiescence with regard to the Office's rejections. Applicants reserve the right to pursue any subject matter removed or modified by this amendment in a related divisional, continuation or continuation-in-part application.

The drawings were objected to because of reasons cited on attached form PTO 948.

Corrected drawings are attached to this response. Applicants respectfully submit that the Office's objection has been obviated. Additionally, a request for amendment of the drawings (Figures 6-12 and 14-20) has been submitted under separate cover as per MPEP 608.02(r). Applicants respectfully submit that support for the changes can be found in the sequence listing as filed and that none of the changes constitutes new matter.